Study guide
9.4 NGS Quality Metrics, Coverage Depth & Bioinformatics
ASCP Molecular Biology Technologist MB
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Strategy
1.1 ASCP MB Exam Structure, Eligibility Routes & Policies 1.2 Computer Adaptive Testing (CAT) & Scoring Mechanics 1.3 Blueprint Navigation & Preparation Strategy
2 Nucleic Acid Chemistry & Molecular Structure
2.1 DNA Structure, Nitrogenous Bases & Thermodynamic Stability 2.2 RNA Types, Secondary Structure & Chemical Lability 2.3 Chromatin Organization, Histone Modifications & DNA Methylation
3 Central Dogma, Genome Organization & Cytogenetics
3.1 DNA Replication Machinery & Enzymology 3.2 Transcription, Translation & Genetic Code 3.3 Mutations, Polymorphisms & Chromosomal Aberrations
4 Biochemical Reagents & Enzymes
4.1 DNA Polymerases, Reverse Transcriptases & Proofreading 4.2 Restriction Endonucleases, Ligases & Nucleases 4.3 Reaction Buffers, Cations & Master Mix Additives
5 Nucleic Acid Isolation & Purification
5.1 Organic & Inorganic Extraction Chemistries 5.2 Solid-Phase Silica Columns & Magnetic Bead Isolation 5.3 Specimen-Specific Lysis & Challenging Matrices
6 Nucleic Acid Quantification & Electrophoresis
6.1 UV Spectrophotometry & Fluorometry 6.2 Agarose & Polyacrylamide Gel Electrophoresis 6.3 Capillary Electrophoresis & Microfluidic Bioanalyzers 6.4 Mass Spectrometry (MALDI-TOF) in Molecular Diagnostics
7 PCR Principles & Primer Design Optimization
7.1 Conventional PCR Thermodynamics & Cycling Kinetics 7.2 Primer Design Criteria, Melting Temp & Secondary Structures 7.3 PCR Inhibition, Facilitators & Troubleshooting
8 Advanced Amplification Technologies
8.1 Real-Time qPCR Probe Chemistries & Fluorescent Dyes 8.2 qPCR Quantification (Standard Curve, ΔΔCt) & Dissociation Melt Curve Analysis 8.3 Digital PCR (dPCR), Droplet Partitioning & Poisson Absolute Quantification 8.4 Isothermal & Target Multiplex Amplification
9 DNA Sequencing Technologies
9.1 Sanger Dideoxy Sequencing & Electropherogram Interpretation 9.2 NGS Library Preparation, Fragmentation & Target Enrichment 9.3 Massively Parallel NGS Platforms & Chemistries 9.4 NGS Quality Metrics, Coverage Depth & Bioinformatics
10 Hybridization, Blotting & Cytogenetic Assays
10.1 Southern, Northern & Dot Blot Chemistries 10.2 Fluorescence In Situ Hybridization (FISH) & CISH 10.3 Microarrays & Array Comparative Genomic Hybridization (aCGH)
11 Molecular Infectious Disease Diagnostics
11.1 Quantitative Viral Load Monitoring (HIV-1, HCV, HBV, CMV) 11.2 Qualitative Multiplex Syndromic Pathogen Panels 11.3 Antimicrobial Resistance Genotyping 11.4 Molecular Epidemiology & Pathogen Typing
12 Molecular Oncology & Hematopathology
12.1 Hematologic Malignancies & Translocation Assays 12.2 Solid Tumor Somatic Driver Mutations 12.3 Microsatellite Instability & DNA Mismatch Repair 12.4 Liquid Biopsy, ctDNA & Minimal Residual Disease
13 Medical Genetics, Pharmacogenomics & Identity Testing
13.1 Single-Gene Mendelian Disorders & CFTR Testing 13.2 Trinucleotide Repeat Expansion Disorders 13.3 Clinical Pharmacogenomics (PGx) Core Alleles 13.4 Human Identity Testing & Post-Transplant Chimerism
14 Quality Assurance, Controls & Method Validation
14.1 Quality Assurance Controls & Reference Materials 14.2 Clinical Method Validation & Performance Characteristics 14.3 Quality Management, Proficiency Testing & Competency
15 Laboratory Operations, Safety & Clinical Variant Reporting
15.1 Physical Facility Design & Unidirectional Workflow 15.2 Laboratory Biosafety, Chemical Hygiene & Waste 15.3 Clinical Calculations, ACMG Variant Classification & HGVS
9.4 NGS Quality Metrics, Coverage Depth & Bioinformatics
Key Takeaways Explain This Topic AI
The Phred quality score (Q-score) quantitatively defines base-calling error probability via Q = -10 log10(P), where Q30 represents 99.9% base call accuracy (1 in 1,000 error rate), serving as the clinical diagnostic quality benchmark.
Coverage depth dictates analytical sensitivity: germline variant detection requires 30X–100X depth, whereas somatic oncology panels require 500X–2,000X+ depth with high uniformity to detect low-frequency mutant alleles (VAF 1%–5%).
The secondary bioinformatics pipeline executes quality trimming (FastQC), sequence alignment to human reference genomes (GRCh37/hg19 or GRCh38/hg38 via BWA-MEM), PCR duplicate removal (Picard), and variant calling (GATK, Mutect2).
Variant Call Format (VCF) files record genomic coordinates, reference/alternate alleles, and genotype fields including Genotype (GT), Allele Depth (AD), Read Depth (DP), and Variant Allele Frequency (VAF).
Clinical NGS quality assurance requires monitoring run metrics, contamination thresholds (VerifyBamID), GC-content coverage bias, and pseudogene homologous alignment artifacts.
Last updated: August 2026
9.4 NGS Quality Metrics, Coverage Depth & Bioinformatics
Quick Summary: Converting millions of raw optical or electronic sequencing signals into validated clinical diagnostic reports requires a structured bioinformatic pipeline and rigorous quality control checkpoints. The Phred quality score ( Q Q Q -score) quantifies base-calling accuracy, with Q 30 Q30 Q 30 (99.9% accuracy, 1 in 1,000 error rate) serving as the clinical quality standard. Analytical sensitivity depends on coverage depth (fold coverage) and uniformity , ranging from 30 X– 100 X 30\text{X}–100\text{X} 30 X –100 X for constitutional germline testing to 500 X– 2 , 000 X + 500\text{X}–2,000\text{X}+ 500 X –2 , 000 X + for somatic oncology panels detecting low-frequency variant allele fractions ( 1 % – 5 % 1\%–5\% 1%–5% VAF). The bioinformatic workflow progresses from primary base calling ( FASTQ ) through secondary alignment ( SAM/BAM ) and variant calling ( VCF ), concluding with tertiary clinical annotation against public disease databases (ClinVar, COSMIC, gnomAD) and AMP/ASCO/CAP or ACMG/AMP tier classifications.
1. Phred Quality Scores ( Q Q Q -Score) & The FASTQ Architecture
The fundamental metric of base-calling reliability is the Phred Quality Score ( Q Q Q ) , defined logarithmically as: Q = − 10 log 10 ( P error ) ⟺ P error = 10 − Q 10 Q = -10 \log_{10}(P_{\text{error}}) \iff P_{\text{error}} = 10^{-\frac{Q}{10}} Q = − 10 lo g 10 ( P error ) ⟺ P error = 1 0 − 10 Q
where P error P_{\text{error}} P error is the estimated probability that the assigned base call is incorrect. +---------------------------------------------------------------------------------------------------------+
- | PHRED QUALITY SCORE CALIBRATION |
- +-------------+-----------------------------+-----------------------+-------------------------------------+
- | Phred Score | Probability of Error (P) | Base Call Accuracy | Clinical Diagnostic Status |
- +-------------+-----------------------------+-----------------------+-------------------------------------+
- | **Q10** | $1\text{ in } 10$ ($0.10$) | $90.0\%$ | Unacceptable; high error rate |
- | **Q20** | $1\text{ in } 100$ ($0.01$) | $99.0\%$ | Minimum acceptable research cutoff |
- | **Q30** | $1\text{ in } 1,000$ ($0.001$)| $99.9\%$ | **Clinical diagnostic standard** |
- | **Q40** | $1\text{ in } 10,000$ ($0.0001$)| $99.99\%$ | High-accuracy benchmark |
- +-------------+-----------------------------+-----------------------+-------------------------------------+
Clinical Benchmark: Accredited clinical diagnostic NGS assays generally require that ≥ 80 % \ge 80\% ≥ 80% to 85 % 85\% 85% of all sequenced bases in a run achieve ≥ Q 30 \ge Q30 ≥ Q 30 .
The FASTQ File Format Architecture
Primary analysis software converts raw binary base calls (BCL files on Illumina) into FASTQ text files. Every single sequenced read is represented by a standardized 4-line entry : @M01234:105:000000000-A8B9C:1:1101:14250:1820 1:N:0:TCGAAGTC
- NATTCGATCGATCGATCGATCGATCGATCGATCGATCGATCGATCGA
- +
- #AAFFFFJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJJF
Line 1 (Header @ ): Unique read identifier containing instrument ID ( M01234 ), run number ( 105 ), flow cell ID, lane ( 1 ), tile ( 1101 ), X/Y cluster coordinates ( 14250:1820 ), read pair member ( 1 or 2 ), filter pass status ( N ), and the sample index barcode ( TCGAAGTC ).
Line 2 (Sequence): The raw nucleotide base calls ( A , C , G , T , or N for ambiguous calls).
Line 3 (Separator + ): Delimiter line, optionally repeating the header identifier.
Line 4 (Quality String): ASCII-encoded Phred quality scores corresponding 1-to-1 with the bases in Line 2. Under the standard Phred+33 offset (Sanger/Illumina 1.8+): ASCII Character Code = Q + 33 \text{ASCII Character Code} = Q + 33 ASCII Character Code = Q + 33
(e.g., Q 30 + 33 = 63 Q30 + 33 = 63 Q 30 + 33 = 63 , corresponding to the ASCII character ? ; Q 40 + 33 = 73 Q40 + 33 = 73 Q 40 + 33 = 73 , corresponding to I ).
2. Coverage Metrics: Depth, Breadth & Uniformity
Coverage metrics establish the statistical power and analytical limit of detection of an NGS assay. COVERAGE METRICS DEFINED
- Target Region: ================================================ (Gene Exon: 500 bp)
- Read 1: ------------>
- Read 2: ------------>
- Read 3: ------------>
- Read 4: ------------>
- Read 5: ------------>
- Read 6: ------------>
- Read Depth (Fold Coverage): Number of overlapping reads covering a single base locus (e.g., 500X)
- Breadth of Coverage: Percentage of the 500 bp target region covered at or above a threshold (e.g., 100% >= 100X)
- Uniformity: Evenness of read distribution across all exons (minimal high peaks or dropout valleys)
Mathematical Calculation of Theoretical Fold Coverage ( X X X ) Depth ( X ) = N × L G \text{Depth } (X) = \frac{N \times L}{G} Depth ( X ) = G N × L
where N N N is the total number of reads generated, L L L is the average read length in base pairs, and G G G is the total target genome or panel size in base pairs.
Germline vs. Somatic Clinical Depth Standards
Germline Testing (Hereditary Cancer, Mendelian Genetics):
Target Depth: 30 X– 100 X 30\text{X}–100\text{X} 30 X –100 X .
Rationale: Constitutional variants are present at expected frequencies of either 50 % 50\% 50% (heterozygous) or 100 % 100\% 100% (homozygous) . At 50 X 50\text{X} 50 X depth, a heterozygous allele is supported by ∼ 25 \sim 25 ∼ 25 independent reads, providing overwhelming statistical confidence for variant calling.
Somatic Oncology Testing (Solid Tumors & Hematologic Malignancies):
Target Depth: 500 X– 2 , 000 X + 500\text{X}–2,000\text{X}+ 500 X –2 , 000 X + .
Rationale: Clinical tumor specimens are heterogeneous mixtures containing non-neoplastic stromal cells, infiltrating lymphocytes, tumor aneuploidy, and subclonal driver mutations. Somatic panels must reliably detect mutations at 1 % – 5 % 1\%–5\% 1%–5% Variant Allele Frequency (VAF) . At 1 , 000 X 1,000\text{X} 1 , 000 X depth, a 2 % 2\% 2% VAF subclonal mutation is supported by 20 independent reads, meeting statistical thresholds for confident clinical reporting.
Liquid Biopsy / Cell-Free Tumor DNA (ctDNA) & Minimal Residual Disease (MRD):
Target Depth: 5 , 000 X– 20 , 000 X + 5,000\text{X}–20,000\text{X}+ 5 , 000 X –20 , 000 X + combined with Unique Molecular Identifiers (UMIs) to detect mutant fragments at 0.01 % – 0.1 % 0.01\%–0.1\% 0.01%–0.1% VAF.
3. The Secondary Bioinformatics Pipeline: FASTQ to BAM
Secondary analysis transforms raw, unaligned reads into aligned, coordinate-sorted, deduplicated alignments. THE SECONDARY BIOINFORMATICS PIPELINE WORKFLOW
- +-------------------------------------------------------------------------+
- | 1. Quality Control & Trimming: FastQC -> Adapter Trimming (Trimmomatic) |
- +------------------------------------+------------------------------------+
- |
- v
- +-------------------------------------------------------------------------+
- | 2. Read Alignment: BWA-MEM maps reads to Reference Genome (hg19 / hg38) |
- | Generates Sequence Alignment/Map (SAM) -> Binary Alignment Map (BAM) |
- +------------------------------------+------------------------------------+
- |
- v
- +-------------------------------------------------------------------------+
- | 3. Post-Alignment Processing: Coordinate Sorting & Indexing (BAI) |
- | PCR Duplicate Marking/Removal (Picard) + Base Recalibration (BQSR) |
- +------------------------------------+------------------------------------+
- |
- v
- +-------------------------------------------------------------------------+
- | 4. Variant Calling: GATK HaplotypeCaller (Germline) / Mutect2 (Somatic) |
- | Generates Variant Call Format (VCF) File |
- +-------------------------------------------------------------------------+
- Key Pipeline Stages and Algorithms
Read Alignment (Mapping):
Reads are mapped to the human reference genome— GRCh37 (hg19) or GRCh38 (hg38) .
BWA-MEM (Burrows-Wheeler Aligner): The clinical standard for short-read DNA alignment, utilizing the Burrows-Wheeler transform and Ferragina-Manzini (FM) index to rapidly align millions of reads with high mapping quality ( M Q MQ MQ ).
Splice-Aware Aligners (STAR, HISAT2): Used for RNA-sequencing to allow reads to span large non-coding introns across exon-exon junctions.
File Formats (SAM, BAM, BAI):
SAM (Sequence Alignment/Map): Human-readable, tab-delimited text file containing alignment coordinates, mapping quality scores, and CIGAR strings (e.g., 100M = 100 bp match; 50M2I48M = 2 bp insertion).
BAM (Binary Alignment Map): Highly compressed, BGZF binary representation of SAM. Coordinates must be sorted numerically by chromosome and position.
BAI (BAM Index): Accompanying index file enabling visualization software like the Integrated Genomics Viewer (IGV) to instantly retrieve and render reads at any genomic locus.
PCR Duplicate Removal (Deduplication):
Multiple reads sharing identical 5' mapping coordinates arise from in vitro PCR amplification of the same original DNA fragment during library prep.
Algorithms (Picard MarkDuplicates , Sambamba) flag duplicate reads, retaining only a single read with the highest quality score for variant calling. This prevents PCR amplification artifacts from artificially inflating coverage depth or skewing variant allele frequencies.
4. Variant Call Format (VCF) Architecture & Format Fields
Variant calling algorithms (e.g., GATK HaplotypeCaller for germline, Mutect2 / Strelka2 for somatic) analyze aligned BAM files and output candidate variants in a standardized VCFv4.2 file. ANATOMY OF A CLINICAL VCF ENTRY
- #CHROM POS ID REF ALT QUAL FILTER INFO FORMAT PATIENT_TUMOR
- chr7 140453136 rs121913342 T A 1500 PASS DP=1000;AF=0.25 GT:AD:DP:GQ 0/1:750,250:1000:99
- Dissecting the VCF Fields
#CHROM & POS : Chromosome and 1-based coordinate (e.g., chr7:140453136 , the locus of the BRAF V600E mutation).
REF & ALT : Reference nucleotide ( T ) and alternate mutant nucleotide ( A ).
FILTER : PASS indicates the variant met all clinical quality thresholds; failures list specific flags (e.g., LowQual , StrandBias , LowDepth ).
FORMAT and Sample Genotype Sub-Fields:
GT (Genotype): 0/0 = Homozygous Reference; 0/1 = Heterozygous Alternate; 1/1 = Homozygous Alternate.
AD (Allele Depth): Raw count of reads supporting each allele in the order Ref_Count,Alt_Count (e.g., 750,250 ).
DP (Depth): Total filtered read depth at the locus ( 1000 ).
GQ (Genotype Quality): Phred-scaled confidence in the genotype call ( 99 = maximum confidence).
Calculating Variant Allele Frequency (VAF)
Variant Allele Frequency represents the proportion of sequencing reads supporting the mutant allele: VAF = Alt Read Depth Ref Read Depth + Alt Read Depth = AD [ 1 ] AD [ 0 ] + AD [ 1 ] = 250 750 + 250 = 0.25 ( 25.0 % ) \text{VAF} = \frac{\text{Alt Read Depth}}{\text{Ref Read Depth} + \text{Alt Read Depth}} = \frac{\text{AD}[1]}{\text{AD}[0] + \text{AD}[1]} = \frac{250}{750 + 250} = \mathbf{0.25 \quad (25.0\%)} VAF = Ref Read Depth + Alt Read Depth Alt Read Depth = AD [ 0 ] + AD [ 1 ] AD [ 1 ] = 750 + 250 250 = 0.25 ( 25.0% )
5. Tertiary Analysis, Annotation & Clinical Variant Interpretation
Tertiary analysis interprets called variants within clinical and pathological contexts. +---------------------------------------------------------------------------------------------------------+
- | CLINICAL VARIANT CLASSIFICATION FRAMEWORKS |
- +---------------------+-----------------------------------+-----------------------------------------------+
- | Framework | Tier / Classification Levels | Diagnostic & Therapeutic Actionability |
- +---------------------+-----------------------------------+-----------------------------------------------+
- | **AMP / ASCO / CAP**| **Tier I:** Strong Clinical Sig. | Biomarkers predicting response to FDA-approved|
- | **Somatic Oncology**| (Therapeutic, Diagnostic, Prog.) | therapies in standard-of-care guidelines. |
- | **System (2017)** +-----------------------------------+-----------------------------------------------+
- | | **Tier II:** Potential Clin. Sig. | Investigational therapies in clinical trials; |
- | | | off-label therapeutic indications. |
- | +-----------------------------------+-----------------------------------------------+
- | | **Tier III:** Unknown Sig. (VUS) | Variants of Uncertain Significance. |
- | +-----------------------------------+-----------------------------------------------+
- | | **Tier IV:** Benign / Likely Ben. | Common population polymorphisms (gnomAD >1%). |
- +---------------------+-----------------------------------+-----------------------------------------------+
- | **ACMG / AMP** | **Class 5:** Pathogenic | >99% certainty of causing disease. |
- | **Germline System** +-----------------------------------+-----------------------------------------------+
- | **(2015)** | **Class 4:** Likely Pathogenic | >90% certainty of causing disease. |
- | +-----------------------------------+-----------------------------------------------+
- | | **Class 3:** VUS | Uncertain Significance (insufficient evidence)|
- | +-----------------------------------+-----------------------------------------------+
- | | **Class 2:** Likely Benign | >90% probability of being benign. |
- | +-----------------------------------+-----------------------------------------------+
- | | **Class 1:** Benign | Documented non-pathogenic polymorphism. |
- +---------------------+-----------------------------------+-----------------------------------------------+
- Essential Annotation Databases
Population Polymorphism Databases: gnomAD (Genome Aggregation Database) — variants with population allele frequencies > 1 % >1\% > 1% in gnomAD are generally classified as benign polymorphisms rather than causative germline disease alleles.
Somatic Cancer Knowledgebases: COSMIC (Catalogue of Somatic Mutations in Cancer) , OncoKB , CIViC .
Germline Mutation Archives: ClinVar , HGMD (Human Gene Mutation Database) .
6. Clinical NGS Quality Assurance & Bioinformatic Failure Modes
Sample Cross-Contamination: Evaluated using bioinformatic tools such as VerifyBamID , which detect excess heterozygous base calls at invariant homozygous single nucleotide loci. Sample contamination exceeding 1 % – 2 % 1\%–2\% 1%–2% requires specimen repeat.
GC Coverage Bias: Regions with extreme GC content ( > 70 % >70\% > 70% GC, such as the CEBPA or TERT promoter; or < 25 % <25\% < 25% GC) amplify poorly during PCR, resulting in severe coverage valleys or complete allele dropouts.
Pseudogene Interference: Highly homologous pseudogenes (e.g., PMS2 vs. PMS2CL , SMN1 vs. SMN2 , CYP2D6 vs. CYP2D7 ) share > 98 % >98\% > 98% sequence identity with functional genes. Short 150 bp 150\text{ bp} 150 bp NGS reads frequently misalign to the pseudogene, creating false-positive mutation calls or masking true pathogenic variants. Resolution requires long-read sequencing (PacBio HiFi), Multiplex Ligation-dependent Probe Amplification (MLPA), or specialized pseudogene-masking bioinformatic pipelines.
FFPE Cytosine Deamination Artifacts: Formalin fixation induces hydrolytic deamination of unmethylated cytosines into uracils ( C → U C \rightarrow U C → U ). During library PCR amplification, DNA polymerase reads uracil as thymine, creating artificial C > T C>T C > T / G > A G>A G > A transition artifacts at low variant allele frequencies ( 1 % – 5 % 1\%–5\% 1%–5% ). Treating FFPE DNA with Uracil-DNA Glycosylase (UDG) prior to library construction excises uracil bases, eliminating false-positive deamination calls.